browse around this site 投稿者：Kimberly 投稿日：2026/01/12(Mon) 04:39 No.17122643 
Fcγ receptor kind IIIA polymorphism infuences therapy outcomes in patients with rheumatoid arthritis handled with rituximab. 57.Ruyssen-Witrand A, Rouanet S, Combe B, et al. T promoter polymorphism within the B-cell activating issue gene and the response to rituximab in rheumatoid arthritis patients. 58.Fabris M, Quartuccio L, Lombardi S, et al. C IL-6 polymorphism predicts a decrease efficacy of rituximab therapy in rheumatoid arthritis. 59.Sellam J, Rouanet S, Hendel-Chavez H, et al. Blood reminiscence B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritis. 60.Sellam J, Rouanet S, Hendel-Chavez H, et al. CCL19, a B cell chemokine, is said to the lower of blood reminiscence B cells and predicts the clinical response to rituximab in patients with rheumatoid arthritis. 61.Owczarczyk Okay, Lal P, Abbas AR, et al. A plasmablast biomarker for nonresponse to antibody therapy to CD20 in rheumatoid arthritis. 62.van Vollenhoven RF, Emery P, Bingham CO, third, et al. Longterm security of patients receiving rituximab in rheumatoid arthritis clinical trials.
Look at my website - amgen rituximab biosimilar (browse around this site (https://www.facebook.com/rituximabprecio/)) |
- 返信フォーム
- 記事修正＆削除フォーム